Nature Communications (Dec 2019)
Artificially cloaked viral nanovaccine for cancer immunotherapy
- Manlio Fusciello,
- Flavia Fontana,
- Siri Tähtinen,
- Cristian Capasso,
- Sara Feola,
- Beatriz Martins,
- Jacopo Chiaro,
- Karita Peltonen,
- Leena Ylösmäki,
- Erkko Ylösmäki,
- Firas Hamdan,
- Otto K. Kari,
- Joseph Ndika,
- Harri Alenius,
- Arto Urtti,
- Jouni T. Hirvonen,
- Hélder A. Santos,
- Vincenzo Cerullo
Affiliations
- Manlio Fusciello
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Flavia Fontana
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki
- Siri Tähtinen
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Cristian Capasso
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Sara Feola
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Beatriz Martins
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Jacopo Chiaro
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Karita Peltonen
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Leena Ylösmäki
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Erkko Ylösmäki
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Firas Hamdan
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Otto K. Kari
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Joseph Ndika
- Systems Toxicology Group, Department of Bacteriology and Immunology, Medicum, University of Helsinki
- Harri Alenius
- Systems Toxicology Group, Department of Bacteriology and Immunology, Medicum, University of Helsinki
- Arto Urtti
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- Jouni T. Hirvonen
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki
- Hélder A. Santos
- Drug Research Program, Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki
- Vincenzo Cerullo
- Drug Research Program, Division of Pharmaceutical Biosciences and Digital Precision Cancer Medicine Flagship (iCAN), Faculty of Pharmacy, University of Helsinki
- DOI
- https://doi.org/10.1038/s41467-019-13744-8
- Journal volume & issue
-
Vol. 10,
no. 1
pp. 1 – 13
Abstract
Cancer therapy using oncolytic virus has shown pre-clinical and clinical efficacy. Here, the authors report ExtraCRAd, an oncolytic virus cloaked with tumour cell membrane and report its therapeutic effects in vitro and in vivo in multiple mouse tumour models.
